Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study – A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines

This publication has 11 references indexed in Scilit:

• Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study
  Nature Communications, 2022
• An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
  EBioMedicine, 2022
• Global impact of the first year of COVID-19 vaccination: a mathematical modelling study
  The Lancet Infectious Diseases, 2022
• Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial
  The Lancet Respiratory Medicine, 2022
• Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial
  The Lancet, 2022
• Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
  Cell, 2021
• Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
  The Lancet, 2021
• Sustained T Cell Immunity, Protection and Boosting Using Extended Dosing Intervals of BNT162b2 mRNA Vaccine
  SSRN Electronic Journal, 2021
• Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
  The Lancet, 2020
• Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19
  Nature Immunology, 2020